Our Take
A successful tech transfer is not a clinical win, but the 9-month timeline and titer gains matter for biotech timelines where manufacturing delays routinely derail programs.
Why it matters
Neuroblastoma carries high mortality in children, and Daretabart showed 86% three-year overall survival in phase 2 (company-reported). Manufacturing speed directly impacts how fast this therapy reaches patients in BLA submission.
Do this week
CDMO stakeholders: audit your own bench-to-GMP handoff timelines against this 9-month baseline to identify bottlenecks in titer optimization or scale-up validation.
Tech transfer completed in 9 months with titer gains
Aragen has finished the technology transfer and first commercial-scale GMP manufacturing runs for Renaissance Pharma's Daretabart, a humanised anti-GD2 monoclonal antibody targeting high-risk neuroblastoma. The transfer moved from Aragen's early-stage site in Morgan Hill, California to the company's new commercial biologics facility in Bengaluru, India. The process included a several-fold increase in titer and right-first-time execution from bench to 2 KL GMP scale.
Daretabart received FDA Fast Track Designation in April 2026. Phase 2 data showed 73.7% event-free survival and 86% overall survival at three years in children with high-risk neuroblastoma (company-reported).
The Bengaluru facility is equipped with multiple 2 KL bioreactors supporting both scale-up and scale-out modes. At full capacity, it can produce 60-70 batches annually with a turnaround of one batch every 4-5 days (company-reported). The facility also operates in parallel scale-out mode with two 2 KL bioreactors in parallel to deliver a 4 KL batch size, supporting both fed-batch and intensified fed-batch production.
This marks the sixth programme to transition from early-phase development in Morgan Hill to clinical supply in Bengaluru under Aragen's dual-hub model. The company invested $40 million in the Bengaluru facility.
Manufacturing speed reduces BLA timeline risk
Neuroblastoma remains one of the most lethal pediatric cancers. Phase 2 survival data of 86% at three years is clinically substantial, but the molecule reaches patients only if manufacturing capacity exists when the BLA enters review. Biotech programs routinely miss regulatory timelines because CDMO capacity lags development pace or tech transfer extends beyond 12 months.
A 9-month handoff with titer gains and right-first-time GMP execution shortens the path to commercial readiness. Batch turnaround of 4-5 days at 2 KL scale removes a common constraint on clinical supply during pivotal trials and early post-approval demand.
The ability to scale out (two 2 KL runs in parallel) adds operational flexibility for surge manufacturing without redesigning the process or moving to larger single-reactor campaigns, which carry higher failure risk in GMP validation.
What to track in your own CDMO relationships
If you oversee biotech manufacturing partnerships, benchmark your tech-transfer timeline against this 9-month result. Delays past 12 months signal gaps in process documentation, scale-up methodology, or CDMO capacity planning. Ask your CDMO partner whether they measure titer improvement as a formal success criterion, not a side effect, and whether their facility design includes built-in scale-out capacity to avoid single-point failures on batch turnaround.
Request right-first-time execution metrics from your previous transfers. If the first GMP run required deviation or repeat batches, your process window is narrower than it should be. That risk compounds when the drug is pediatric-labeled and has limited manufacturing slots before launch.